| Name | Title | Contact Details |
|---|---|---|
Mike Milkovich |
Chief Technology Officer | Profile |
Capnia, Inc., a privately held company headquartered in Redwood City, California, develops diagnostics based on its proprietary Sensalyze™ technology for precision metering of gas flow.
AllerVie Health is a national network of board-certified allergists and immunologists partnering together for the advancement of patient care, serving patients across 12 states in 76 clinic locations. Our providers are committed to establishing the allergy and immunology gold standard, expanding access to best-in-class care, and bringing relief and renewed vitality to the millions of Americans affected annually, many of whom live in underserved communities today. AllerVie is relentlessly dedicated to clinical excellence, creating an improved patient experience, and supporting the development of advanced allergy and immunology-focused therapeutics and treatment options. With AllerVie Health, our patients can feel their best, reclaim their lives, and live in freedom!
VirtuOx is the worlds largest provider of Respiratory, Sleep and Insomnia Testing in the privacy and comfort of your home!
Established in 2005, Butterfly Effects is one of the nation`s leading providers of individually tailored community-based ABA (Applied Behavior Analysis) therapy services for all ages of individuals with autism and other related disabilities. We help children and adults at all development levels, and assist families in instilling positive, lasting changes for their loved ones.
ForSight VISION5, Inc. (www.forsightvision5.com), was founded in January of 2011 as the fifth company to emerge from the ophthalmic incubator ForSight Labs, LLC (www.forsightlabs.com). ForSight VISION5 is focused on developing non-invasive drug delivery products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. ForSight VISION5`s lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to receive medication continually. The Helios insert is restricted to investigational use only and has not been approved by the Food and Drug Administration or any other regulatory authority for commercial distribution.